Mary Miller - Sep 26, 2023 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role: Chief Legal Officer
Signature: /s/ Rasmus Holm-Jorgensen, Attorney-in-Fact
Stock symbol: ACRV
Transactions as of: Sep 26, 2023
Transactions value $: $0
Form type: 4
Date filed: 9/28/2023, 07:17 PM
Previous filing: Mar 24, 2022
Next filing: Oct 19, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACRV	Common Stock	Award	$0	+3.86K	+9.54%	$0.00	44.3K	Sep 26, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACRV	Stock Option (Right to Buy)	Award	$0	+11.6K		$0.00	11.6K	Sep 26, 2023	Common Stock	11.6K	$8.95	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, twenty-five percent (25%) shall vest on October 1, 2024, and the remaining RSUs shall vest in three substantially equal annual installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.
F2	Twenty-five percent (25%) of the shares subject to the option shall vest on October 1, 2024, and the remaining shares subject to the option shall vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.

Content

These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, twenty-five percent (25%) shall vest on October 1, 2024, and the remaining RSUs shall vest in three substantially equal annual installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.

Twenty-five percent (25%) of the shares subject to the option shall vest on October 1, 2024, and the remaining shares subject to the option shall vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.